Wilner G D, Nossel H L, LeRoy E C
J Clin Invest. 1968 Dec;47(12):2608-15. doi: 10.1172/JCI105943.
Purified acid-soluble and insoluble human collagen accelerated the clotting of plateletpoor plasma in silicone-treated tubes. The clot-promoting effect did not appear to be due to thromboplastic activity since the collagen preparations did not activate factor X in the presence of factor VII and calcium. Instead, collagen appeared to accelerate clotting by activating Hageman factor (factor XII) on the basis of the following findings: collagen increased the clot-promoting activity of partially purified Hageman factor but exerted no further effect in the presence of kaolin, a known activator of Hageman factor; clot-promoting eluates were obtained from collagen exposed to normal, hemophilic, or PTC-deficient plasma but not from collagen exposed to Hageman or PTA-deficient plasma. The collagen molecule itself appeared to be required for the clot-promoting activity since digestion with collagenase or thermal denaturation at pH 2.5 (about 35 degrees C) resulted in very marked reduction in clot-promoting activity. Since thermal denaturation is associated with transformation of collagen structure from triple helical to random coil form, it is suggested that the native form of collagen is essential for the ability to activate Hageman factor. Blockage of the free amino groups by treatment with nitrous acid or dinitrofluorobenzene only slightly reduced the clot-promoting activity of collagen. In contrast, since addition of cationic proteins to collagen markedly reduced pro-coagulant activity it is suggested that negatively charged sites on the collagen molecule are critical for Hageman factor activation. This suggestion is supported by the finding that pepsin treatment of collagen, which removes the predominantly negatively charged telopeptides, results in significant decrease in coagulant activity. Esterification of collagen, which neutralizes 80-90% of the free carboxyl groups, reduced coagulant activity by over 90% and it is suggested that the free carboxyl groups of glutamic and aspartic acids provide the negatively charged sites critical for Hageman factor activation.
纯化的酸溶性和酸不溶性人胶原蛋白可加速经硅处理的试管中乏血小板血浆的凝血。这种促凝作用似乎并非由于组织凝血活酶活性,因为在存在因子VII和钙的情况下,胶原蛋白制剂并未激活因子X。相反,基于以下发现,胶原蛋白似乎是通过激活哈格曼因子(因子XII)来加速凝血的:胶原蛋白增加了部分纯化的哈格曼因子的促凝活性,但在高岭土(一种已知的哈格曼因子激活剂)存在的情况下没有进一步作用;从暴露于正常、血友病或PTC缺乏血浆的胶原蛋白中获得了促凝洗脱液,但从暴露于哈格曼或PTA缺乏血浆的胶原蛋白中未获得。促凝活性似乎需要胶原蛋白分子本身,因为用胶原酶消化或在pH 2.5(约35摄氏度)下热变性会导致促凝活性显著降低。由于热变性与胶原蛋白结构从三螺旋形式转变为无规卷曲形式有关,因此表明胶原蛋白的天然形式对于激活哈格曼因子的能力至关重要。用亚硝酸或二硝基氟苯处理封闭游离氨基只会略微降低胶原蛋白的促凝活性。相比之下,由于向胶原蛋白中添加阳离子蛋白会显著降低促凝活性,因此表明胶原蛋白分子上带负电荷的位点对于哈格曼因子激活至关重要。这一观点得到以下发现的支持:用胃蛋白酶处理胶原蛋白会去除主要带负电荷的端肽,导致凝血活性显著降低。胶原蛋白的酯化作用可中和80 - 90%的游离羧基基团,使凝血活性降低超过90%,因此表明谷氨酸和天冬氨酸的游离羧基基团提供了对于哈格曼因子激活至关重要的带负电荷位点。